{"id":"NCT01128738","sponsor":"GlaxoSmithKline","briefTitle":"GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Including an Open-label Phase to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Axillary Hyperhidrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2010-05-24","resultsPosted":"2012-04-25","lastUpdate":"2015-06-08"},"enrollment":152,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperhidrosis"],"interventions":[{"type":"DRUG","name":"GSK1358820","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"GSK1358820","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to demonstrate superiority of single treatment of GSK1358820 (hereinafter, referred to as BOTOX®) over placebo in terms of the efficacy of treatment with BOTOX® 50 U in each axilla (100 U in total for each patient) as intradermal injections based on gravimetric assessment (measurement of spontaneous axillary sweat production) for axillary hyperhidrosis.","primaryOutcome":{"measure":"Percentage of Responders Assessed by Gravimetric Measurement at Week 4 in the First Treatment Phase","timeFrame":"Week 4","effectByArm":[{"arm":"BTX 50 U in First and Second TPs","deltaMin":96.2,"sd":null},{"arm":"Placebo in First TP; BTX 50 U in Second TP","deltaMin":45.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":22},"locations":{"siteCount":14,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":144},"commonTop":["Nasopharyngitis"]}}